Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC14 in Adult Patients With Dengue Fever
NCT03875560Phase 2Withdrawn
- Sponsor
- Implicit Bioscience
- Start
- May 2019
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of atibuclimab in dengue fever, sponsored by Implicit Bioscience. Planned start May 2019; status: withdrawn.
02
Drugs
atibuclimab
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT03875560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875560.